1. MARKET INTRODUCTION 1.1 Market Definition 24 1.2 Objective of the Study 24 1.3 Limitation 24 1.4 Stakeholders 25 1.5 Currency used in the Report 25 1.6 Scope of the Global Regenerative Medicine Market Study 25 2. RESEARCH METHODOLOGY OR ASSUMPTION 26 2.1 Research Methodology for Global Regenerative Medicine Market Study 26 2.1.1 Main objective of the Global Regenerative Medicine Market Study 27 3. INDUSTRY PERFORMANCE 28 4. EXECUTIVE SUMMARY 29 4.1 Key Facts on Cancer and Cardiovascular Diseases (CVDs), Global 30 5. MARKET OVERVIEW 32 5.1 Market Introduction 32 5.1.1 Cord Blood and Regenerative Medicine 32 5.2 Market Drivers 33 5.2.1 Growing Prevalence of Genetic Disorders and Chronic Diseases 33 5.2.2 Rising Pipeline of the Regenerative Medicine Products 36 5.2.3 The transformative potential of CAR T 38 5.2.3.1 Adoption of traditional healthcare settings to administer CARTs 40 5.2.3.2 Enabling rapid innovation of cell therapy with solid tumors 41 5.2.4 Technological Advancements in Regenerative Medicine 41 5.3 Market Challenges 45 5.3.1 High Cost Associated with Regenerative Medicines 45 5.3.2 Ethical Issues related to the use of Stem Cell & Regenerative Medicines 47 5.4 Market Opportunities 49 5.4.1 Increasing Number of Products in the Pipeline 49 5.4.2 Rising Number of Organ Transplantation 50 6. REIMBURSEMENT POLICY 52 6.1 General Overview 52 6.1.1 Reimbursement in Japan and the European Union 52 6.1.2 Reimbursement in the United Kingdom 52 6.1.3 Reimbursement in the United States 53 6.1.3.1 Establish cost-effectiveness 54 6.1.3.2 Explore innovative payment plans with payers 54 6.1.3.3 Engage providers and coordinate care 55 6.1.3.4 Offer patient assistance programs to address unique circumstances 55 6.1.3.5 Utilize alternative distribution channels 55 7. LEGAL & REGULATORY FRAMEWORK 57 7.1 General Overview 57 7.2 FDA’s Framework for Regenerative Medicine 64 7.3 Europe 67 7.4 Regenerative Medicine Product in Japan Under Pharmaceuticals and Medical Devices Act (PMD ACT) 67 7.4.1 The basic structure of NHI Pricing in Japan 68 7.5 Regulation of Regenerative Medicine in India 71 8. DEMAND AND SUPPLY SIDE ANALYSIS 73 8.1 Demand Side Analysis 73 8.2 Supply Side Analysis 75 8.2.1 Select Significant Clinical & Data Events: Q3 2019 77 8.2.1.1 Gene Therapy & Genome Editing Programs 77 8.2.1.2 Cell-Based Immuno-Oncology Programs 78 8.2.1.3 Cell Therapy Programs 79 8.2.2 Top Partnerships under Regenerative Medicine 84 8.2.3 Top Mergers & Acquisitions under Regenerative Medicine 90 8.2.4 Top Business Expansion & Investment under Regenerative Medicine 94 9. VALUE CHAIN ANALYSIS 96 9.1 Value Chain Analysis 96 10. MARKET INSIGHTS BY PRODUCT 98 10.1 General Overview 98 10.1.1 Cell Therapy 99 10.1.2 Gene Therapy 100 10.1.3 Tissue Engineering 102 10.1.4 Small Molecule and Biologics 107 11. REGENERATIVE MEDICINE MARKET INSIGHTS, BY MATERIAL TYPE 115 11.1 General Overview 115 11.1.1 Synthetic Materials 117 11.1.2 Biologically Derived Materials 118 11.1.3 Genetically Engineered Materials 120 11.1.4 Others (Pharmaceuticals) 121 12. REGENERATIVE MEDICINE MARKET INSIGHTS, BY APPLICATION 123 12.1 General Overview 123 12.1.1 Cardiovascular 124 12.1.2 Oncology 127 12.1.3 Dermatology 132 12.1.4 Musculoskeletal 134 12.1.5 Immunology and Inflammation 137 12.1.6 Ophthalmology 140 12.1.7 Neurology 142 12.1.8 Others 144 13. MARKET INSIGHTS BY REGION 146 13.1 General Overview 146 13.2 North America Regenerative Medicine Market (2019-2026) 147 13.2.1 North America Regenerative Medicine Market by Product 148 13.2.2 North America Regenerative Medicine Market by Material Type 149 13.2.3 North America Regenerative Medicine Market by Application 149 13.2.4 North America Regenerative Medicine Market by Country 150 13.2.4.1 US Regenerative Medicine Market (2019-2026) 150 13.2.4.2 US Healthcare Expenditure 152 13.2.4.2.1 Health Spending by Type of Service or Product 152 13.2.4.2.2 Health Spending by Major Sources of Funds 153 13.2.4.2.3 Facts on Heart Disease in the US 153 13.2.4.2.4 Facts on Coronary Heart Disease (CHD) in the US 154 13.2.4.2.5 Facts on Stroke in the US 154 13.2.4.2.6 US Regenerative Medicine Market by Product 155 13.2.4.2.7 US Regenerative Medicine Market by Material Type 156 13.2.4.2.8 US Regenerative Medicine Market by Application 156 13.2.4.3 Canada Regenerative Medicine Market (2019-2026) 157 13.2.4.3.1 Facts on Heart Disease in Canada 159 13.2.4.3.2 Canada Regenerative Medicine Market by Product 160 13.2.4.3.3 Canada Regenerative Medicine Market by Material Type 161 13.2.4.3.4 Canada Regenerative Medicine Market by Application 161 13.2.4.4 Rest of North America Regenerative Medicine Devices Market (2019-2026) 162 13.2.4.4.1 Rest of NA Regenerative Medicine Market by Product 162 13.2.4.4.2 Rest of NA Regenerative Medicine Market by Material Type 163 13.2.4.4.3 Rest of NA Regenerative Medicine Market by Application 163 13.3 Europe Regenerative Medicine Market 164 13.3.1 Facts on Cardiovascular Disease in Europe 166 13.3.2 Europe Regenerative Medicine Market by Product 167 13.3.3 Europe Regenerative Medicine Market by Material Type 168 13.3.4 Europe Regenerative Medicine Market by Application 168 13.3.5 Europe Regenerative Medicine Market by Country 169 13.3.5.1 Germany Regenerative Medicine Market (2019-2026) 169 13.3.5.1.1 Germany Regenerative Medicine Market by Product 171 13.3.5.1.2 Germany Regenerative Medicine Market by Material Type 171 13.3.5.1.3 Germany Regenerative Medicine Market by Application 172 13.3.5.2 United Kingdom Regenerative Medicine Market 172 13.3.5.2.1 United Kingdom Healthcare Expenditure 174 13.3.5.2.2 UK Regenerative Medicine Market by Product 176 13.3.5.2.3 UK Regenerative Medicine Market by Material Type 177 13.3.5.2.4 UK Regenerative Medicine Market by Application 177 13.3.5.3 France Regenerative Medicine Market (2019-2026) 178 13.3.5.3.1 France Regenerative Medicine Market by Product 179 13.3.5.3.2 France Regenerative Medicine Market by Material Type 180 13.3.5.3.3 France Regenerative Medicine Market by Application 180 13.3.5.4 Italy Regenerative Medicine Market 181 13.3.5.4.1 Key Facts of Healthcare Spending - Italy in 2018, by Region 182 13.3.5.4.2 Italy Regenerative Medicine Market by Product 184 13.3.5.4.3 Italy Regenerative Medicine Market by Material Type 184 13.3.5.4.4 Italy Regenerative Medicine Market by Application 185 13.3.5.5 Spain Regenerative Medicine Market 185 13.3.5.5.1 Spain Healthcare Expenditure Statistics 187 13.3.5.5.2 Spain Regenerative Medicine Market by Product 188 13.3.5.5.3 Spain Regenerative Medicine Market by Material Type 188 13.3.5.5.4 Spain Regenerative Medicine Market by Application 189 13.3.5.6 Rest of Europe Regenerative Medicine Market (2019-2026) 189 13.3.5.6.1 Rest of Europe Regenerative Medicine Market by Product 191 13.3.5.6.2 Rest of Europe Regenerative Medicine Market by Material Type 191 13.3.5.6.3 Rest of Europe Regenerative Medicine Market by Application 192 13.4 Asia Pacific Regenerative Medicine Market 192 13.4.1 Asia-Pacific Regenerative Medicine Market by Product 193 13.4.2 Asia-Pacific Regenerative Medicine Market by Material Type 194 13.4.3 Asia-Pacific Regenerative Medicine Market by Application 194 13.4.4 Asia-Pacific Regenerative Medicine Market by Country 195 13.4.4.1 China Regenerative Medicine Market (2019-2026) 195 13.4.4.1.1 China Regenerative Medicine Market by Product 198 13.4.4.1.2 China Regenerative Medicine Market by Material Type 199 13.4.4.1.3 China Regenerative Medicine Market by Application 199 13.4.4.2 Japan Regenerative Medicine Market 200 13.4.4.2.1 Japan Regenerative Medicine Market by Product 202 13.4.4.2.2 Japan Regenerative Medicine Market by Material Type 203 13.4.4.2.3 Japan Regenerative Medicine Market by Application 203 13.4.4.3 India Regenerative Medicine Market 204 13.4.4.3.1 Current Trends in Regenerative Medicine in India 204 13.4.4.3.2 India Regenerative Medicine Market by Product 206 13.4.4.3.3 India Regenerative Medicine Market by Material Type 207 13.4.4.3.4 India Regenerative Medicine Market by Application 207 13.4.4.4 Australia Regenerative Medicine Market (2019-2026) 208 13.4.4.4.1 Australia Regenerative Medicine Market by Product 210 13.4.4.4.2 Australia Regenerative Medicine Market by Material Type 211 13.4.4.4.3 Australia Regenerative Medicine Market by Application 211 13.4.4.5 South Korea Regenerative Medicine Market 212 13.4.4.5.1 South Korea Regenerative Medicine Market by Product 212 13.4.4.5.2 South Korea Regenerative Medicine Market by Material Type 213 13.4.4.5.3 South Korea Regenerative Medicine Market by Application 213 13.4.4.6 Rest of Asia-Pacific Regenerative Medicine Market (2019-2026) 214 13.4.4.6.1 Rest of APAC Regenerative Medicine Market by Product 215 13.4.4.6.2 Rest of APAC Regenerative Medicine Market by Material Type 215 13.4.4.6.3 Rest of APAC Regenerative Medicine Market by Application 216 13.5 Rest of World Regenerative Medicine Market (2019-2026) 216 13.5.1 Rest of World Regenerative Medicine Market by Product 217 13.5.2 Rest of World Regenerative Medicine Market by Material Type 218 13.5.3 Rest of World Regenerative Medicine Market by Application 218 13.5.4 Rest of World Regenerative Medicine Market by Country 219 13.5.4.1 Brazil Regenerative Medicine Market (2019-2026) 219 13.5.4.1.1 Brazil Regenerative Medicine Market by Product 222 13.5.4.1.2 Brazil Regenerative Medicine Market by Material Type 222 13.5.4.1.3 Brazil Regenerative Medicine Market by Application 223 13.5.4.2 South Africa Regenerative Medicine Market (2019-2026) 223 13.5.4.2.1 South Africa Regenerative Medicine Market by Product 224 13.5.4.2.2 South Africa Regenerative Medicine Market by Material Type 225 13.5.4.2.3 South Africa Regenerative Medicine Market by Application 225 13.5.4.3 Other RoW Countries Regenerative Medicine Market (2019-2026) 226 13.5.4.3.1 Other RoW Regenerative Medicine Market by Product 226 13.5.4.3.2 Other RoW Regenerative Medicine Market by Material Type 227 13.5.4.3.3 Other RoW Regenerative Medicine Market by Application 227 14. COMPETITIVE SCENARIO 228 14.1 Porter’s Five forces analysis 228 14.1.1 Bargaining power of the Supplier 228 14.1.2 Bargaining power of Buyer 228 14.1.3 Industry Rivalry 229 14.1.4 Availability of Substitute 229 14.1.5 Threat of New Entrants 229 14.2 Market Share Analysis, by Company 2019 229 14.2.1 Market Share of Key Players in Regenerative Medicine, 2019 230 15. TOP COMPANY PROFILES 232 15.1 Athersys, Inc 232 15.1.1 Key Facts 232 15.1.2 Business Description 233 15.1.3 Key Product/Services Offerings 233 15.1.4 Growth Strategy 233 15.1.5 SWOT Analysis 234 15.1.6 Key Financials 235 15.1.6.1 Revenue Split 236 15.1.7 Recent Developments 236 15.1.7.1 Partnerships 236 15.1.7.2 Business Expansions and Investment 237 15.2 Corline Biomedical AB 238 15.2.1 Key Facts 238 15.2.2 Business Description 239 15.2.3 Key Product/Services Offerings 239 15.2.4 Growth Strategy 239 15.2.5 SWOT Analysis 240 15.2.6 Key Financials 241 15.2.6.1 Revenue Split 242 15.2.7 Recent Developments 242 15.2.7.1 Partnerships 242 15.3 Mesoblast 243 15.3.1 Key Facts 243 15.3.2 Major Shareholders 243 15.3.3 Business Description 244 15.3.4 Key Product/Services Offerings 244 15.3.5 Growth Strategy 244 15.3.6 SWOT Analysis 245 15.3.7 Key Financials 246 15.3.8 Recent Developments 247 15.3.8.1 Partnerships 247 15.3.8.2 Business Expansions and Investment 247 15.4 NuVasive, Inc. 248 15.4.1 Key Facts 248 15.4.2 Business Description 248 15.4.3 Key Product/Services Offerings 249 15.4.4 Growth Strategy 249 15.4.5 SWOT Analysis 251 15.4.6 Key Financials 252 15.4.6.1 Revenue Split, by Region and Segment 253 15.4.7 Recent Developments 253 15.4.7.1 Product Launches 253 15.4.7.2 Business Expansions and Investment 254 15.4.7.3 Merger and Acquisition 254 15.5 Cook Biotech 255 15.5.1 Key Facts 255 15.5.2 Business Description 255 15.5.3 Key Product/Services Offerings 255 15.5.4 Growth Strategy 256 15.5.5 SWOT Analysis 256 15.5.6 Recent Developments 257 15.5.6.1 Partnerships 257 15.5.6.2 Mergers and Acquisitions 257 15.6 Integra LifeSciences 258 15.6.1 Key Facts 258 15.6.2 Major Shareholders 258 15.6.3 Business Description 259 15.6.4 Key Product/Services Offerings 259 15.6.5 Growth Strategy 260 15.6.6 SWOT Analysis 261 15.6.7 Key Financials 262 15.6.7.1 Revenue Split 263 15.6.8 Recent Developments 264 15.6.8.1 Product Launches 264 15.6.8.2 Partnerships 265 15.6.8.3 Mergers and Acquisitions 265 15.7 Organogenesis 267 15.7.1 Key Facts 267 15.7.2 Business Description 267 15.7.3 Key Product/Services Offerings 268 15.7.4 Growth Strategy 268 15.7.5 SWOT Analysis 270 15.7.6 Key Financials 271 15.7.7 Recent Developments 272 15.7.7.1 Product Launches 272 15.7.7.2 Mergers and Acquisitions 273 15.8 Osiris Therapeutics, Inc 274 15.8.1 Osiris Therapeutics, Inc Key Facts 274 15.8.2 Business Description 274 15.8.3 Key Product/Services Offerings 274 15.8.4 Growth Strategy 275 15.8.5 SWOT Analysis 276 15.8.6 Key Financials 277 15.8.6.1 Revenue Split 278 15.8.7 Recent Developments 278 15.8.7.1 Product Launches 278 15.8.7.2 Mergers and Acquisitions 279 15.9 Stryker Corporation 280 15.9.1 Key Facts 280 15.9.2 Business Description 280 15.9.3 Key Product/Services Offerings 281 15.9.4 Growth Strategy 281 15.9.5 SWOT Analysis 282 15.9.6 Key Financials 283 15.9.6.1 Revenue Split 284 15.9.7 Recent Developments 284 15.9.7.1 Merger and Acquisition 284 15.10 U.S. Stem Cell Inc. 286 15.10.1 Key Facts 286 15.10.2 Business Description 286 15.10.3 Key Product/Services Offerings 286 15.10.4 Growth Strategy 286 15.10.5 SWOT Analysis 287 15.10.6 Key Financials 288 15.10.7 Recent Developments 289 15.10.7.1 Business Expansion 289 15.11 Spark Therapeutics, Inc. 290 15.11.1 Key Facts 290 15.11.2 Business Description 290 15.11.3 Product Segmentation 290 15.11.4 Growth Strategy 291 15.11.5 SWOT Analysis 292 15.11.6 Key Financials 293 15.11.6.1 Revenue Split, by Region and Segment 294 15.11.7 Recent Developments 294 15.11.7.1 Product Launches 294 15.11.7.2 Partnerships 294 15.11.7.3 Mergers and Acquisitions 295 15.12 Pfizer 296 15.12.1 Key Facts 296 15.12.2 Business Description 297 15.12.3 Key Product/Services Offerings 297 15.12.4 Growth Strategy 298 15.12.5 SWOT Analysis 299 15.12.6 Key Financials 300 15.12.6.1 Revenue Split 301 15.12.7 Recent Developments 301 15.12.7.1 Product Launches 301 15.12.7.2 Partnerships 302 15.12.7.3 Mergers and Acquisitions 302 15.13 REGENXBIO Inc. 303 15.13.1 Key Facts 303 15.13.2 Ownership Structure 303 15.13.3 Business Description 304 15.13.4 Key Product/Services Offerings 304 15.13.5 Growth Strategy 304 15.13.6 SWOT Analysis 306 15.13.7 Key Financials 307 15.13.8 Recent Developments 308 15.13.8.1 Partnerships 308 15.13.8.2 Business Expansions and Investment 308 15.13.8.3 Mergers and Acquisitions 309 15.14 Abbott Laboratories 310 15.14.1 Key Facts 310 15.14.2 Business Description 310 15.14.3 Key Product/Services Offerings 311 15.14.1 SWOT Analysis 312 15.14.2 Key Financials 313 15.14.2.1 Revenue Split 314 15.14.3 Recent Developments 314 15.14.3.1 Product Launches 314 15.14.3.2 Partnership 315 15.14.3.3 Merger and Acquisition 315 15.15 Roche Holding AG 316 15.15.1 Key Facts 316 15.15.2 Business Description 316 15.15.3 Key Product/Services Offerings 317 15.15.4 SWOT Analysis 318 15.15.5 Key Financials 319 15.15.5.1 Revenue Split 320 15.15.6 Recent Developments 320 15.15.6.1 Product Launches 320 15.15.6.2 Partnerships 323 15.15.6.3 Mergers and Acquisitions 324 15.16 Sarepta Therapeutics 325 15.16.1 Key Facts 325 15.16.2 Business Description 325 15.16.3 Key Product/Services Offerings 325 15.16.4 Growth Strategy 326 15.16.5 SWOT Analysis 326 15.16.6 Key Financials 327 15.16.6.1 Revenue Split 328 15.16.7 Recent Developments 328 15.16.7.1 Partnerships 328 15.17 Gilead Sciences, Inc. 330 15.17.1 Key Facts 330 15.17.2 Business Description 330 15.17.3 Key Product/Services Offerings 331 15.17.4 Growth Strategy 331 15.17.5 SWOT Analysis 332 15.17.6 Key Financials 333 15.17.6.1 Revenue Split, by Region and Segment 334 15.17.7 Recent Developments 334 15.17.7.1 Product Launches 334 15.17.7.2 Partnerships 335 15.17.7.3 Business Expansions and Investment 337 15.17.7.4 Mergers and Acquisitions 338

FIG. 1 Scope of the Global Regenerative Medicine Market Study 25 FIG. 2 Research Methodology for Global Regenerative Medicine Market Study 26 FIG. 3 Global Regenerative Medicine Market Size, 2019-2026 (US$ Billion) 31 FIG. 4 Chronic Disease in America 33 FIG. 5 Cardiovascular diseases (CVDs) at a Glance, 2017 34 FIG. 6 Total number of deaths due to cardiovascular diseases in the world 2017: 17.3m 35 FIG. 7 Direct Cost of CVD is expected to double from 2011 to 2025 36 FIG. 8 Schematic of Process for Predicting Cell And Gene Therapy Product Launches And Penetration Rate 37 FIG. 9 Impact on patients by CAR-T Activity 39 FIG. 10 Current Strategies in Regenerative Medicine 42 FIG. 11 One-Time Gene Therapies Worth Price in US$ Mn 47 FIG. 12 Transplants Performed in 2018 by Organ, United States 51 FIG. 13 Transplants Performed in 2018 by Organ, United States 51 FIG. 14 Summary of Unique Attributes of Many Gene and Cell Therapies and Their Implications 56 FIG. 15 Summary of Unique Attributes of Many Gene and Cell Therapies and Their Implications 56 FIG. 16 Stem Cell Clinics Operating in the United States, May 2017 64 FIG. 17 FDA Determining Regulation of a Regenerative Therapy 66 FIG. 18 Expedited Approval System Under PMD Act 68 FIG. 19 Cost Calculation Method 69 FIG. 20 Cost Calculation Method 70 FIG. 21 Global Cancer Incidence 73 FIG. 22 Supply Chain of Regenerative Medicine 76 FIG. 23 Total Global Financings by Type, by Year, US$ Bn 77 FIG. 24 Total Merger and Acquisitions: Upfront Payments, US$ Bn 77 FIG. 25 Value Chain of Regenerative Medicine 96 FIG. 26 Manufacturing of Tissue-Engineered Medical Product 96 FIG. 27 Global Regenerative Medicine Market Share, by Product, 2019 & 2026 (%) 98 FIG. 28 Global Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 98 FIG. 29 Global Cell Therapy Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 100 FIG. 30 Number of Clinical Trials Utilizing Specific RM/AT Technology: 2018 101 FIG. 31 Global Gene Therapy Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 102 FIG. 32 Path for clinical translation of bone tissue engineered biomaterials, cell-based therapies and growth factors (and other bioactive molecules) that prove effective, first preclinically and then in clinical trials 106 FIG. 33 Global Tissue Engineering Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 107 FIG. 34 Novel FDA approvals since 2000 109 FIG. 35 2018’s Potential Blockbuster Approvals 109 FIG. 36 CDER approvals by therapeutic area in 2018 114 FIG. 37 Global Small Molecule and Biologics Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 114 FIG. 38 Biomaterials for scaffolding 115 FIG. 39 Global Regenerative Medicine Market Share, by Material Type, 2019 & 2026 (%) 116 FIG. 40 Global Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 116 FIG. 41 Global Synthetic Materials Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 118 FIG. 42 Global Biologically Derived Materials Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 119 FIG. 43 Global Genetically Engineered Materials Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 120 FIG. 44 Global Other (Pharmaceuticals) Materials Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 122 FIG. 45 Clinical Trials by Indication: Till Q3 2019 123 FIG. 46 Global Regenerative Medicine Market Share, by Application, 2019 & 2026 (%) 124 FIG. 47 Representation of biomaterial strategies to tackle different post-MI phases 125 FIG. 48 Global Cardiovascular Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 126 FIG. 49 Companies with Preclinical or Clinical Oncology-Focused Regenerative Medicine Therapies 128 FIG. 50 Regenerative Medicine Clinical Trials in Oncology 129 FIG. 51 Regenerative Medicine Clinical Trials in Oncology, By Technology 129 FIG. 52 Regenerative Medicine Clinical Trials in Oncology, By Technology 130 FIG. 53 Global Landscape: RM/AT Developers Active in Oncology 130 FIG. 54 Global Regenerative Medicine Financings in Oncology, in US$ Million 131 FIG. 55 Global Oncology Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 131 FIG. 56 Regenerative Medicine in Dermatology: Advantages and Stepwise Implementation 132 FIG. 57 Origin of adult human tissues from embryonic stem cells 133 FIG. 58 Global Dermatology Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 134 FIG. 59 Benefits and Drawbacks of Using Adult Stem Cells and Pluripotent Stem Cells For Clinical Applications 136 FIG. 60 Derivation of pluripotent stem cells and subsequent tissue generation ability 136 FIG. 61 Global Musculoskeletal Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 137 FIG. 62 Global Immunology and Inflammation Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 139 FIG. 63 Global Ophthalmology Regenerative Medicine Market Size, by Region, 2020-26 (US$ Bn) 141 FIG. 64 Annual Incidence of Most Common Adult-Onset Neurologic Disorders 142 FIG. 65 Medicines in Development for Neurological Disorders 143 FIG. 66 Global Neurology Regenerative Medicine Market Size, by Region, 2019-26 (US$ Bn) 143 FIG. 67 Clinical Trials of Regenerative Medicines for Rare Disease 145 FIG. 68 Global Other Regenerative Medicine Application Market Size, by Region, 2019-26 (US$ Bn) 145 FIG. 69 Global Regenerative Medicine Market by Region, 2020 & 2026 (%) 146 FIG. 70 Global Regenerative Medicine Market by Region, 2019-26 (US$ Billion) 146 FIG. 71 North America Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 148 FIG. 72 North America Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 149 FIG. 73 North America Regenerative Medicine Market by Country, 2019-26 (US$ Billion) 150 FIG. 74 US Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 155 FIG. 75 US Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 156 FIG. 76 Canada Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 160 FIG. 77 Canada Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 161 FIG. 78 Rest of NA Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 162 FIG. 79 Rest of NA Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 163 FIG. 80 Schematic illustration of successes and failures in the commercialization of ATMPs in the EU 164 FIG. 81 The annual cost of CVD in the US$ in billion 166 FIG. 82 Europe Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 167 FIG. 83 Europe Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 168 FIG. 84 Germany Health Spending 170 FIG. 85 Germany Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 171 FIG. 86 Germany Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 171 FIG. 87 Health Expenditure by Country, Total expenditure, US$ Million 174 FIG. 88 Health Expenditure by Country, Expenditure Per Head, US$ Million 175 FIG. 89 UK Government Health Expenditure, 2013-2017 175 FIG. 90 UK Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 176 FIG. 91 UK Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 177 FIG. 92 Proportional mortality in France by Disease Type (%) 179 FIG. 93 France Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 179 FIG. 94 France Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 180 FIG. 95 Five-year survival rates for various cancers are above the EU average 181 FIG. 96 Out of Pocket (OOP) payments make up a higher proportion of health spending than the EU average 182 FIG. 97 Causes of Death in Italy by Gender, (%) 2014 182 FIG. 98 Public healthcare expenditure in Italy in 2018, by region (in million US$) 183 FIG. 99 Italy Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 184 FIG. 100 Italy Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 184 FIG. 101 Number of New Cancer Cases in 2018, Both Sexes, All Ages 186 FIG. 102 Number of New Cancer Cases in 2018, Males & Females 186 FIG. 103 Healthcare expenditure per capita in Spain in 2017, by sector and autonomous community, US$ 187 FIG. 104 Spain Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 188 FIG. 105 Spain Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 188 FIG. 106 Rest of Europe Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 191 FIG. 107 Rest of Europe Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 191 FIG. 108 Asia-Pacific Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 193 FIG. 109 Asia-Pacific Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 194 FIG. 111 China Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 198 FIG. 112 China Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 199 FIG. 113 Death rate of heart diseases among Japanese males from 2007 to 2016 (per 100,000 population) 200 FIG. 114 Estimated Number of Cancer Incidence by Site, Males (2018) 201 FIG. 115 Estimated Number of Cancer Incidence by Site, Females (2018) 201 FIG. 116 Japan Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 202 FIG. 117 Japan Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 203 FIG. 119 India Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 206 FIG. 120 India Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 207 FIG. 122 Australia Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 210 FIG. 123 Australia Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 211 FIG. 124 South Korea Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 212 FIG. 125 South Korea Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 213 FIG. 126 Treatment History at Regeneration Center of Thailand 214 FIG. 127 Rest of APAC Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 215 FIG. 128 Rest of APAC Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 215 FIG. 129 Rest of World Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 217 FIG. 130 Rest of World Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 218 FIG. 131 Rest of World Regenerative Medicine Market by Country, 2019-26 (US$ Billion) 219 FIG. 132 Brazil Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 222 FIG. 133 Brazil Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 222 FIG. 134 South Africa Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 224 FIG. 135 South Africa Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 225 FIG. 136 Other RoW Regenerative Medicine Market Size, by Product, 2019-26 (US$ Bn) 226 FIG. 137 Other RoW Regenerative Medicine Market Size, by Material Type, 2019-26 (US$ Bn) 227 FIG. 138 Porter’s Five forces analysis of the Global Regenerative Medicine Market 228 FIG. 139 Market Share of Key Players in Regenerative Medicine, 2019 (%) 230 FIG. 140 Athersys, Inc Collaboration & Partnerships 234 FIG. 141 Athersys, Inc, SWOT Analysis 234 FIG. 142 Key Financials of Athersys, Inc 235 FIG. 143 Athersys, Inc Revenue Split, 2018 236 FIG. 144 Corline Biomedical AB 240 FIG. 145 Corline Biomedical AB, SWOT Analysis 240 FIG. 146 Key Financials of Corline Biomedical AB 241 FIG. 147 Corline Biomedical., Revenue Split, 2018 242 FIG. 148 Mesoblast 245 FIG. 149 Mesoblast, SWOT Analysis 245 FIG. 150 Key Financials of Mesoblast 246 FIG. 151 NuVasive inc. Services 251 FIG. 152 Nuvasive Inc., SWOT Analysis 251 FIG. 153 Nuvasive Inc., Key Financials 252 FIG. 154 Nuvasive Inc., Revenue Split, 2018 253 FIG. 155 Cook Biotech SWOT Analysis 256 FIG. 156 Integra LifeSciences, Brand Promises 260 FIG. 157 Integra LifeSciences, SWOT Analysis 261 FIG. 158 Integra LifeSciences, Key Financials 262 FIG. 159 Integra LifeSciences, Revenue Split, 2018 263 FIG. 160 Organogenesis Timeline 270 FIG. 161 Organogenesis SWOT Analysis 270 FIG. 162 Key Financials of Organogenesis 271 FIG. 163 Osiris Therapeutics, Grafix- Product Specifications 275 FIG. 164 Osiris Therapeutics, SWOT Analysis 276 FIG. 165 Key Financials of Osiris Therapeutics 277 FIG. 166 Osiris Therapeutics, Revenue Split, 2018 278 FIG. 167 Stryker Corporation Focus Areas & Initiatives 282 FIG. 168 Stryker Corporation, SWOT Analysis 282 FIG. 169 Key Financials of Stryker Corporation 283 FIG. 170 Stryker Corporation Revenue Split, 2018 284 FIG. 171 U.S. Stem Cell Inc. SWOT Analysis 287 FIG. 172 Key Financials of U.S. Stem Cell Inc. 288 FIG. 173 Spark Therapeutics, Inc. Company Technologies 291 FIG. 174 Spark Therapeutics, SWOT Analysis 292 FIG. 175 Key Financials of Spark Therapeutics, Inc. 293 FIG. 176 Spark Therapeutics, Inc., Revenue Split, 2018 294 FIG. 177 Pfizer Inc., Summary 299 FIG. 178 Pfizer Inc., SWOT Analysis 299 FIG. 179 Key Financials of Pfizer Inc. 300 FIG. 180 Pfizer Inc., Revenue Split, 2018 301 FIG. 181 REGENXBIO Inc., NAV Technology Platform 305 FIG. 182 REGENXBIO Inc. SWOT Analysis 306 FIG. 183 Key Financials of REGENXBIO Inc. 307 FIG. 184 Abbott laboratories Solutions for Diagnostics 311 FIG. 185 Abbott laboratories SWOT Analysis 312 FIG. 186 Key Financials of Abbott Laboratories 313 FIG. 187 Abbott Laboratories Revenue Split, 2018 314 FIG. 188 Roche, Top-selling Diagnostics Product Portfolios in 2018 (CHF millions) 317 FIG. 189 Roche Strategy 318 FIG. 190 Roche SWOT Analysis 318 FIG. 191 Key Financials of Roche 319 FIG. 192 Roche Revenue Split, 2017 320 FIG. 193 Sarepta Therapeutics, SWOT Analysis 326 FIG. 194 Key Financials of Sarepta Therapeutics 327 FIG. 195 Sarepta Therapeutics, Revenue Split, 2018 328 FIG. 196 Gilead Sciences, Inc., Growth Driver 332 FIG. 197 Gilead Sciences Inc., SWOT Analysis 332 FIG. 198 Key Financials of Gilead Sciences Inc. 333 FIG. 199 Gilead Sciences, Inc., Revenue Split, 2018 334TABLE 1 Cumulative Product Launches Per Year by Disease Group, 2018-2030 37 TABLE 2 Number of cumulative treated patients by disease group, 2018-2030 38 TABLE 3 Regenerative Medicine FDA-Approved Products 43 TABLE 4 Addressable Global Patient Population, by Therapeutic Need, and Mode of Therapy, Population 44 TABLE 5 Addressable Global Patient Population, by Therapeutic Need, and Mode of Therapy, Population 47 TABLE 6 Gene Therapy (in vivo), Number of Assets 50 TABLE 7 Publications on reimbursement/risk-sharing, link with Orphan Drugs 53 TABLE 8 Related to reimbursement of regenerative medicine-based products per country 53 TABLE 9 Priority Review Designation 57 TABLE 10 Orphan Drug Designation 58 TABLE 11 Conditional Approval 59 TABLE 12 Marketing authorization under exceptional circumstances 60 TABLE 13 Marketing authorization under exceptional circumstances 60 TABLE 14 Regulatory Framework Parameters 65 TABLE 15 Structural Versus Non-structural Cells, Tissues 65 TABLE 16 Selected Allogeneic Stem Cell Therapies 66 TABLE 17 GMP Manufacturing Cost and Scale-Up Analysis for Cell-Based Therapies 69 TABLE 18 GMP Manufacturing Cost and Scale-Up Analysis for Cell-Based Therapies 70 TABLE 19 Top Product Launches under Regenerative Medicine 79 TABLE 20 Top Partnerships under Regenerative Medicine 84 TABLE 21 Top Mergers & Acquisitions under Regenerative Medicine 90 TABLE 22 Top Business Expansion & Investment under Regenerative Medicine 94 TABLE 23 FDA Approved Cellular and Gene Therapy Products 101 TABLE 24 List of most commercially available bone tissue-engineered products along with their description 104 TABLE 25 US FDA 510(k) medical devices approved for bone applications between 2011 and 2015 105 TABLE 26 US FDA 510(k) cleared allograft-based medical devices approved between 2011 and 2015 105 TABLE 27 Small molecules regulating the maintenance and proliferation of PSCs 108 TABLE 28 CDER approvals in 2018 110 TABLE 29 Selected Potential Approvals for New Drugs in 2019 113 TABLE 30 Synthesis of synthetic materials for tissue engineering applications using Adipose stem cells (ASCs) 117 TABLE 31 Maximum range of porosity and mechanical strength attained for composite bone scaffolds using protein and polysaccharide biomaterials 119 TABLE 32 Molecules attached to monomeric elastin-like recombinamers and their mechanism of action 120 TABLE 33 Global Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 124 TABLE 34 Exemplar injectable biomaterials used for the in vivo delivery of pro-angiogenic growth factors in animal models of MI 126 TABLE 35 Some of the commercially available skin substitutes that have been successfully used in clinical practice 133 TABLE 36 Overview of Epidemiology and Treatment Options for Musculoskeletal Diseases 135 TABLE 37 Advantages of Gingival Mesenchymal Stem Cells (GMSCs) obtained from current studies in the treatment of Immunological Diseases 138 TABLE 38 List of studies in which the therapeutic potential of administration of GMSCs for the treatment of immunological diseases was obtained 138 TABLE 39 Use of Stem Cells in Ophthalmologic and Oculoplastic Surgery 140 TABLE 40 Programs with products granted Regenerative Medicine Advanced Therapy (RMAT) designation between December 2016 and October 2018 144 TABLE 41 North America Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 149 TABLE 42 Leading Sites of New Cancer Cases and Deaths – 2020 Estimates 151 TABLE 43 US Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 156 TABLE 44 Collaborative Networks and Infrastructure Supporting Regenerative Medicine in Canada 157 TABLE 45 Canada Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 161 TABLE 46 Rest of NA Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 163 TABLE 47 Regenerative Medicine Products approved in Europe 165 TABLE 48 Europe Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 168 TABLE 49 Europe Regenerative Medicine Market Size, by Country, 2019-26 (US$ Bn) 169 TABLE 50 Germany Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 172 TABLE 51 Therapeutic Developments - UK 173 TABLE 52 UK Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 177 TABLE 53 France - Government Health Expenditure 178 TABLE 54 France Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 180 TABLE 55 Italy Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 185 TABLE 56 Spain Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 189 TABLE 57 Rest of Europe Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 192 TABLE 58 Asia-Pacific Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 194 TABLE 59 Asia-Pacific Regenerative Medicine Market Size, by Country, 2019-26 (US$ Bn) 195 TABLE 60 Main Stem Cell Research Institutes in China 196 TABLE 61 Stem Cells Products Approved for Clinic Pre-Clinic Trial by the SFDA 197 TABLE 62 China Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 199 TABLE 63 Japan Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 203 TABLE 64 India Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 207 TABLE 65 Australian Regenerative Medicine Sector Vision and Priority Action Areas 208 TABLE 66 Assessment of the Australian Regenerative Medicine Sector 209 TABLE 67 Australia Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 211 TABLE 68 South Korea Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 213 TABLE 69 Rest of APAC Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 216 TABLE 70 Rest of World Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 218 TABLE 71 Examples of Brazilian Regenerative Medicine Firms 219 TABLE 72 mHealth benefits in 2017 - Brazil 220 TABLE 73 Number of people with the four heart conditions in Brazil, 2015 221 TABLE 74 Brazil Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 223 TABLE 75 South Africa Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 225 TABLE 76 Other RoW Regenerative Medicine Market Size, by Application, 2019-26 (US$ Bn) 227 TABLE 77 Athersys, Inc Key Facts 232 TABLE 78 Athersys, Inc Ownership Structure 232 TABLE 79 Product segmentation of Athersys, Inc 233 TABLE 80 Athersys, Inc Growth Strategy 233 TABLE 81 Athersys, Inc Partnerships 236 TABLE 82 Athersys, Inc Business Expansions, Investment and Divestitures 237 TABLE 83 Corline Biomedical AB Key Facts 238 TABLE 84 Corline Biomedical AB Ownership Structure 238 TABLE 85 Product segmentation of Corline Biomedical AB 239 TABLE 86 Corline Biomedical AB Growth Strategy 239 TABLE 87 Corline Biomedical AB Partnerships 242 TABLE 88 Mesoblast Key Facts 243 TABLE 89 Mesoblast Key Facts 243 TABLE 90 Product segmentation of Mesoblast 244 TABLE 91 Mesoblast Growth Strategy 244 TABLE 92 Mesoblast Partnerships 247 TABLE 93 Mesoblast Business Expansions, Investment and Divestitures 247 TABLE 94 NuVasive, Inc. Key Facts 248 TABLE 95 NuVasive, Inc. Ownership Structure 248 TABLE 96 Product Segmentation of NuVasive 249 TABLE 97 NuVasive Growth Strategy 249 TABLE 98 NuVasive Inc., Product Launches 253 TABLE 99 NuVasive Inc. Business Expansions, Investment and Divestitures 254 TABLE 100 NuVasive Inc. Merger and Acquisition 254 TABLE 101 Cook Biotech Key Facts 255 TABLE 102 Product segmentation of Cook Biotech 255 TABLE 103 Cook Biotech Growth Strategy 256 TABLE 104 Cook Biotech Partnerships 257 TABLE 105 Cook Biotech Industries Mergers and Acquisitions 257 TABLE 106 Integra LifeSciences Key Facts 258 TABLE 107 Integra LifeSciences Major Shareholders 258 TABLE 108 Product Segmentation of Integra LifeSciences 259 TABLE 109 Integra LifeSciences Growth Strategy 260 TABLE 110 Integra LifeSciences Product Launches 264 TABLE 111 Integra LifeSciences Partnerships 265 TABLE 112 Integra LifeSciences Mergers and Acquisitions 265 TABLE 113 Organogenesis Key Facts 267 TABLE 114 Organogenesis Ownership Structure 267 TABLE 115 Product Segmentation of Organogenesis 268 TABLE 116 Organogenesis Growth Strategy 268 TABLE 117 Organogenesis Product Launches 272 TABLE 118 Organogenesis Mergers and Acquisitions 273 TABLE 119 Osiris Therapeutics, Inc Key Facts 274 TABLE 120 Product segmentation of Osiris Therapeutics 274 TABLE 121 Osiris Therapeutics Growth Strategy 275 TABLE 122 Osiris Therapeutics Product Launches 278 TABLE 123 Osiris Therapeutics Merger and Acquisition 279 TABLE 124 Stryker Corporation Key Facts 280 TABLE 125 Stryker Corporation Ownership Structure 280 TABLE 126 Product segmentation of Stryker Corporation 281 TABLE 127 Stryker Corporation Growth Strategy 281 TABLE 128 Stryker Corporation, Merger and Acquisition 284 TABLE 129 U.S. Stem Cell Inc., Key Facts 286 TABLE 130 Product segmentation of Sony Corporation 286 TABLE 131 U.S. Stem Cell Inc., Growth Strategy 286 TABLE 132 U.S. Stem Cell Clinic, Business Expansion 289 TABLE 133 Spark Therapeutics, Inc. Key Facts 290 TABLE 134 Product Segmentation of Spark Therapeutics, Inc. 290 TABLE 135 Spark Therapeutics, Inc. Growth Strategy 291 TABLE 136 Spark Therapeutics, Inc., Product Launches 294 TABLE 137 Spark Therapeutics, Inc., Partnerships 294 TABLE 138 Spark Therapeutics, Inc. Mergers and Acquisitions 295 TABLE 139 Pfizer Key Facts 296 TABLE 140 Pfizer Ownership Structure 296 TABLE 141 Product segmentation of Pfizer Inc. 297 TABLE 142 Pfizer Inc. Growth Strategy 298 TABLE 143 Pfizer Inc., Product Launches 301 TABLE 144 Pfizer Inc., Partnerships 302 TABLE 145 Pfizer Inc., Mergers and Acquisitions 302 TABLE 146 REGENXBIO Inc. Key Facts 303 TABLE 147 REGENXBIO Inc. Ownership Structure 303 TABLE 148 REGENXBIO Inc., Product/Services Offerings 304 TABLE 149 REGENXBIO Inc. Growth Strategy 304 TABLE 150 REGENXBIO Inc. Partnerships 308 TABLE 151 REGENXBIO Inc. Business Expansions, Investment and Divestitures 308 TABLE 152 REGENXBIO Inc. Mergers and Acquisitions 309 TABLE 153 Abbott Laboratories Key Facts 310 TABLE 154 Product segmentation of Abbott Laboratories 311 TABLE 155 Abbott laboratories Growth Strategy 311 TABLE 156 Abbott Laboratories, Inc. Product Launches 314 TABLE 157 Abbott Laboratories, Inc. Partnership 315 TABLE 158 Abbott Laboratories, Inc. Merger and Acquisition 315 TABLE 159 Roche Key Facts 316 TABLE 160 Product segmentation of Roche 317 TABLE 161 Roche Growth Strategy 317 TABLE 162 Roche Product Launches 320 TABLE 163 Roche Partnerships 323 TABLE 164 Roche Mergers and Acquisitions 324 TABLE 165 Sarepta Therapeutics Key Facts 325 TABLE 166 Product segmentation of Sarepta Therapeutics 325 TABLE 167 Sarepta Therapeutics, Growth Strategy 326 TABLE 168 Sarepta Therapeutics. Partnerships 328 TABLE 169 Gilead Sciences, Inc. Key Facts 330 TABLE 170 Gilead Sciences, Inc., Ownership Structure 330 TABLE 171 Product segmentation of Gilead Sciences, Inc. 331 TABLE 172 Gilead Sciences, Inc. Growth Strategy 331 TABLE 173 Gilead Sciences, Inc. Product Launches 334 TABLE 174 Gilead Sciences, Inc. Partnerships 335 TABLE 175 Gilead Sciences, Inc. Business Expansions, Investment and Divestitures 337 TABLE 176 Gilead Sciences, Inc. Mergers and Acquisitions 338

Athersys, Inc., Corline Biomedical AB, Mesoblast, Nuvasive, Inc., Cook Biotech, Integra LifeSciences Corporation, Organogenesis, Osiris Therapeutics, Inc., Stryker Corporation, U.S. Stem Cell, Inc., Spark Therapeutics, Pfizer, REGENXBIO, Abbott Laboratories, Roche, Sarepta Therapeutics, Gilead Sciences